Table 1.
Demographic and headache characteristics in patients in baseline and visits 2 and 3 (N = 59).
| Baseline | Visit 2 (after 1st Cycle) |
Visit 3 (tras 2nd Cycle) |
|
|---|---|---|---|
| Female sex n (%) | 55 (93.2) | ||
| Age mean (SD) | 44 (12) | ||
| Years of CM mean (SD) | 5.09 (4.4) | ||
| Migraine with aura n (%) | 8 (13.6) | ||
| Obesity n (%) | 7 (11.9) | ||
| Sleep disorders n (%) | 14 (23.7) | ||
| Depression n (%) | 21 (35.6) | ||
| Anxiety n (%) | 21 (35.6) | ||
| Depression and anxiety disorder n (%) | 26 (44.1) | ||
| Arterial hypertension n (%) | 4 (6.8) | ||
| Fybromyalgia n (%) | 4 (6.8) | ||
| Medication overuse n (%) | 37 (64.9) | 27 (45.8) | 25 (42.4) |
| Previous OPT mean (SD) | 3.21 (1.28) | ||
| Topiramate n (%) | 37 (62.7) | ||
| Beta-blockers n (%) | 32 (54.2) | ||
| Flunarizine n (%) | 43 (72.9) | ||
| Anti Hypertensive n (%) | 2 (3.4) | ||
| Amitriptyline n (%) | 50 (84.7) | ||
| Others n (%) | 12 (20.3) | ||
| Migraine days mean (SD) | 16.34 (8.26) | 10.92 (6.95) | 11.19 (7.34) |
| Headache days mean (SD) | 23.07 (7.38) | 15.81 (9.53) | 15.24 (9.46) |
| Triptan intake days mean (SD) | 8.96 (9.66) | 5.91 (6.1) | 5.95 (6.23) |
| Analgesic intake days mean (SD) | 15.71 (12.06) | 10.93 (10.74) | 10.49 (10.68) |
| Intensity of headache mean (SD) | 8.24 (1.8) | 7.3 (1.56) | 7.28 (1.50) |
| HIT-6 mean (SD) | 67.11 (6.97) | 63.85 (6.07) | 63.49 (7.34) |
| MIDAS mean (SD) | 71.39 (65.73) | 44 (39.96) | 46.02 (43.99) |
| Conversion to EM n (%) | 18 (30.5) | 16 (27.1) |
SD = Standard deviation; CM = Chronic migraine; OPT = Oral preventive treatment; EM= Episodic migraine; HIT-6 = Headache Impact Test-6; MIDAS = Migraine Disability Assessment Scale.